NovAccel Raises 1.2 Billion JPY in Post-Seed Round Funding
NovAccel, a developer of small superconducting accelerators for medical radioisotope production, has secured 1.2 billion JPY in a post-seed funding round, bringing its total raised capital to approximately 2.0 billion JPY. The funds will accelerate the establishment of an international radium-226 (Ra-226) procurement system and the completion of its medical radioisotope manufacturing facility by the end of the year, essential for the stable supply of Actinium-225 (Ac-225) for next-generation cancer therapies.
📋 Article Processing Timeline
- 📰 Published: May 12, 2026 at 00:16
- 🔍 Collected: May 11, 2026 at 15:31
- 🤖 AI Analyzed: May 11, 2026 at 21:05 (5h 33m after Collected)
NovAccel Co., Ltd. (Headquarters: Tsuchiura City, Ibaraki Prefecture, hereinafter 'NovAccel'), which develops RiSA, a small superconducting accelerator for producing medical radioisotopes that support next-generation cancer treatment, is pleased to announce that it has raised 1.2 billion JPY through a third-party allocation of shares in a post-seed round. This round included existing investor UTEC No. 6 Investment Limited Partnership (hereinafter 'UTEC') and new investors such as Fast Track Initiative No. 4 Investment Limited Partnership (hereinafter 'FTI'), DCI Venture Growth Support No. 2 Investment Limited Partnership (hereinafter 'DCI'), ATOX Co., Ltd. (hereinafter 'ATOX'), and YOSHIDA Co., Ltd. (hereinafter 'YOSHIDA').
This funding will further accelerate the strengthening of the international procurement system for Radium-226 (Ra-226), a raw material, and capital investment towards the completion of the medical radioisotope manufacturing facility within the year.
Furthermore, with this investment, Ms. Hiroko Kimura from FTI has newly been appointed as an external director.
■ Background and Purpose of Funding
NovAccel aims to establish a stable global supply system for Actinium-225 (Ac-225), which is essential for Targeted Alpha Therapy (TAT), a 주목-worthy cancer treatment method. This funding will intensively promote the following four points:
Establishment of an international raw material procurement network
- In September 2025, NovAccel became the first private Japanese company to participate in the 'Global Radium Initiative' led by the International Atomic Energy Agency (IAEA). Concrete negotiations are currently underway with various national governments and public institutions for the procurement of Ra-226, the raw material for Ac-225, and this funding will be allocated to these efforts.
Completion of accelerator manufacturing facility (scheduled for October 2026)
- The development of the independently developed superconducting accelerator RiSA and the maintenance of the isotope manufacturing facility are progressing smoothly. Towards completion in October 2026, we will strengthen the introduction of state-of-the-art equipment and our engineering system.
Implementation of high-purity extraction technology
- Following the recently announced 'Successful high-purity extraction of Ac-225,' we are expediting the establishment of manufacturing processes (SOP) for sample provision starting in Q4 2026. Leveraging the newly raised funds, we will promote the introduction of radiation-shielded glove boxes and the development of automated extraction devices for mass production of Ac-225, while also aiming to establish a GMP-compliant manufacturing system.
Partnership with ATOX and YOSHIDA
- We have welcomed two companies with deep knowledge and extensive experience in the fields of radiation management, shielding, and medical radioisotopes (RI) as business partners. Based on many years of experience in radiation management operations, we aim to optimize safety management and advanced handling techniques in the manufacturing process, striving to achieve a stable supply of high-quality Ac-225 under a safe manufacturing system.
■ Investor Comments
Ms. Hiroko Kimura, FTI
NovAccel is a rare startup founded on Japan's accumulated wisdom in high-energy physics, namely superconducting electron accelerator technology, bringing together experts in physics, medicine, and business. FTI has continued its investment activities to open new frontiers in life sciences. We are confident that NovAccel's endeavor to supply pharmaceutical raw materials from the 'seed of technology' of an accelerator, transcending the frameworks of drug discovery and devices, will create a new ripple in the existing market. In particular, this project, which contributes to solving the supply challenges of Ac-225, is extremely significant in supporting the foundation of next-generation medicine, and we are very pleased to embark on this great challenge together.
Mr. Tomotaka Goji, UTEC
Following the seed round of 730 million JPY conducted by UTEC in July last year, NovAccel's total funding has now reached approximately 2.0 billion JPY with this post-seed round. During this period, NovAccel, with high expectations and sincere cooperation from the government and the radiopharmaceutical industry, has been constructing the supply chain for Ra-226, demonstrating high-purity Ac-225 extraction technology, and developing accelerator manufacturing facilities for Ac-225 sample provision starting in Q4 this year, all at a pace exceeding initial expectations. We are genuinely delighted to welcome FTI and DCI, who have led Japan's venture capital industry, and ATOX and YOSHIDA, who possess unparalleled knowledge and track record in radiation management and medical radioisotopes in Japan, recognizing this progress. As UTEC, we are proud to cooperate for NovAccel's further advancement so that Japan can lead the world in the field of radiopharmaceutical manufacturing.
Mr. Naoyuki Miura, Daiwa Corporate Investment Co., Ltd.
This funding will further accelerate the strengthening of the international procurement system for Radium-226 (Ra-226), a raw material, and capital investment towards the completion of the medical radioisotope manufacturing facility within the year.
Furthermore, with this investment, Ms. Hiroko Kimura from FTI has newly been appointed as an external director.
■ Background and Purpose of Funding
NovAccel aims to establish a stable global supply system for Actinium-225 (Ac-225), which is essential for Targeted Alpha Therapy (TAT), a 주목-worthy cancer treatment method. This funding will intensively promote the following four points:
Establishment of an international raw material procurement network
- In September 2025, NovAccel became the first private Japanese company to participate in the 'Global Radium Initiative' led by the International Atomic Energy Agency (IAEA). Concrete negotiations are currently underway with various national governments and public institutions for the procurement of Ra-226, the raw material for Ac-225, and this funding will be allocated to these efforts.
Completion of accelerator manufacturing facility (scheduled for October 2026)
- The development of the independently developed superconducting accelerator RiSA and the maintenance of the isotope manufacturing facility are progressing smoothly. Towards completion in October 2026, we will strengthen the introduction of state-of-the-art equipment and our engineering system.
Implementation of high-purity extraction technology
- Following the recently announced 'Successful high-purity extraction of Ac-225,' we are expediting the establishment of manufacturing processes (SOP) for sample provision starting in Q4 2026. Leveraging the newly raised funds, we will promote the introduction of radiation-shielded glove boxes and the development of automated extraction devices for mass production of Ac-225, while also aiming to establish a GMP-compliant manufacturing system.
Partnership with ATOX and YOSHIDA
- We have welcomed two companies with deep knowledge and extensive experience in the fields of radiation management, shielding, and medical radioisotopes (RI) as business partners. Based on many years of experience in radiation management operations, we aim to optimize safety management and advanced handling techniques in the manufacturing process, striving to achieve a stable supply of high-quality Ac-225 under a safe manufacturing system.
■ Investor Comments
Ms. Hiroko Kimura, FTI
NovAccel is a rare startup founded on Japan's accumulated wisdom in high-energy physics, namely superconducting electron accelerator technology, bringing together experts in physics, medicine, and business. FTI has continued its investment activities to open new frontiers in life sciences. We are confident that NovAccel's endeavor to supply pharmaceutical raw materials from the 'seed of technology' of an accelerator, transcending the frameworks of drug discovery and devices, will create a new ripple in the existing market. In particular, this project, which contributes to solving the supply challenges of Ac-225, is extremely significant in supporting the foundation of next-generation medicine, and we are very pleased to embark on this great challenge together.
Mr. Tomotaka Goji, UTEC
Following the seed round of 730 million JPY conducted by UTEC in July last year, NovAccel's total funding has now reached approximately 2.0 billion JPY with this post-seed round. During this period, NovAccel, with high expectations and sincere cooperation from the government and the radiopharmaceutical industry, has been constructing the supply chain for Ra-226, demonstrating high-purity Ac-225 extraction technology, and developing accelerator manufacturing facilities for Ac-225 sample provision starting in Q4 this year, all at a pace exceeding initial expectations. We are genuinely delighted to welcome FTI and DCI, who have led Japan's venture capital industry, and ATOX and YOSHIDA, who possess unparalleled knowledge and track record in radiation management and medical radioisotopes in Japan, recognizing this progress. As UTEC, we are proud to cooperate for NovAccel's further advancement so that Japan can lead the world in the field of radiopharmaceutical manufacturing.
Mr. Naoyuki Miura, Daiwa Corporate Investment Co., Ltd.